RIPK1-IN-32
RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC50 of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis[1].
Product Specifications
UNSPSC
12352211
Target
Interleukin Related; NF-κB; p38 MAPK; RIP kinase; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Smiles
[H][C@@]12CC[C@@]([C@]3(C)[C@@](C4=C(C(O[C@H]4C3)=O)CC/C=C(C)/C)([H])C[C@H]5O)(C)[C@@]5([C@]1(CC[C@H]([C@H]2C)OC(CCSSCCC(NOCC6=CC=CC=C6)=O)=O)C)[H]
Molecular Formula
C42H59NO7S2
Molecular Weight
754.05
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; NF-κB; RIPK1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG Immunoglobulin (IG266), CF488A conjugate, 0.1mg/mL
CD106 / VCAM1 (B-K9), CF640R conjugate, 0.1mg/mL
Beta-2-Microglobulin (B2M) (B2M/1118), CF740 conjugate, 0.1mg/mL
N-Cadherin / Cadherin-2 / CD325 (NCAD) (CDH2/1573), CF647 conjugate, 0.1mg/mL
